Polycystic ovary syndrome (PCOS) is a common hormonal disorder affecting 10% to 13% of women of reproductive age worldwide, according to the World Health Organization. Alarmingly, more than two-thirds of those affected are unaware of their condition. The name of the syndrome has long been criticized by women's health experts as misleading and outdated, contributing to poor treatment and misunderstanding. Now, in a landmark move, the condition is officially being renamed polyendocrine metabolic ovarian syndrome, or PMOS, in hopes of improving patient care and reducing confusion.
Why the Name Change?
The term 'polycystic' suggests the presence of multiple cysts on the ovaries, which is not always accurate. Many women with PCOS do not have ovarian cysts, and the condition involves broader metabolic and endocrine issues. Health experts argue that the old name led to misdiagnosis and stigma. The new name, PMOS, emphasizes the metabolic and endocrine aspects, aiming to shift focus to the underlying hormonal imbalances and metabolic dysfunction.
Impact on Diagnosis and Treatment
Renaming the condition is expected to improve awareness and encourage earlier diagnosis. With a more accurate name, healthcare providers may better understand the systemic nature of the disorder, leading to more comprehensive care. This change could also reduce the psychological burden on women who felt stigmatized by the term 'polycystic.'
- PCOS affects 10-13% of women of reproductive age.
- More than two-thirds of cases go undiagnosed.
- The new name PMOS highlights metabolic and endocrine features.
A Global Effort
The renaming was the result of an unprecedented global collaboration among medical experts, patient advocates, and health organizations. This effort aims to bring new hope to millions of women who have struggled with the condition. The change is seen as a critical step toward better care, research, and public understanding.
For more details, read the full story on the Guardian's podcast, featuring assistant science editor Donna Lu and Nour Haydar.
